Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer
, e
17 set 2016
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Research Article
Pubblicato online: 17 set 2016
Pagine: 4 - 16
Ricevuto: 24 feb 2016
Accettato: 04 ago 2016
DOI: https://doi.org/10.1515/fco-2016-0005
Parole chiave
© 2016
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical trials using various therapeutic vaccines_
| STUDY NAME | TARGET ANTIGEN | VACCINE NAME/TYPE | CANCER |
|---|---|---|---|
| IMPACT | PAP | Mo/DCsPAP-GM-CSF | mCRPC |
| PROSPECT | PSA | PSA-TRICOM | mCRPC |
| Stimuvax | MUC1 | BLPD25 | NSCLC |
| PANVAC | MUC1/CEA | DCsPSA-TRICOM | Colorectal |
| GVAX | multiple | T47D&SKBR3 lines | Breast |
| DERMA | MAGE-A3 | Rec Protein | Melanoma |
| MAGRIT | MAGE-A3 | Rec Protein | NSCLC |
| IMPRINT | 11 tumour peptides | soluble | Renal |
| TG4010 | MUC1 | MVA MUC-1-IL-2 | Prostate NSCLC |
| CDX110 | EGFRvIII | Soluble 13-mer | Glioblastoma |